Assorted News from the Last Week: Congratulations to CAC2 Members Autumn Gentry (MACC Fund, Inc) and Mariah Forster Olson (Neuroblastoma Children’s Cancer Society) with inspiration
Assorted News from the Last Week: CAC2 Supporting Member Day One Biopharmaceutical and Ipsen unveiled an ex-U.S. licensing agreement for tovorafenib (approved as Ojemda in
At CAC2 we love to celebrate when our members work together. We offer congratulations to Supporting Organization Day One Biopharmaceuticals and CAC2 member authors and
Assorted News from the Last Week: Congratulations to CAC2 Supporting Organization Day One Biopharmaceuticals and CAC2 member authors and reviewers who contributed to the white
Assorted News from the Last Week: Psychological and ethical issues raised by genomic testing in paediatric care pathway, a qualitative analysis with parents and childhood
The NCI Council of Research Advocates met virtually on June 26 and heard the latest legislative report, with updates on appropriations, cancer-related legislation, and other
Assorted News from the Last Week: Building a case for incorporating patient advocates throughout the research continuum in pediatric oncology. The NCI Council of Research
Assorted News from the Last Week: AWS is providing $10 million to accelerate research for pediatric health care and to better understand rare diseases, including
Assorted News from the Last Week: CAC2 Supporting Organization Member Day One Biopharmaceuticals announced it has entered into an exclusive licensing agreement with MabCare Therapeutics
Assorted News from the Last Week: Bristol Myers Squibb’s Augtyro (repotrectinib) has secured an accelerated approval from the FDA for the treatment of adult and
